Business Context and Reporting Period
Company: Cardio Diagnostics Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2024
Reporting Period: The filing discloses a specific event effective April 3, 2024, regarding the commencement of investor presentations.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose a regulatory communication event.
Material Changes
Regulation FD Disclosure (Item 7.01): Effective April 3, 2024, senior management will begin utilizing the "March 2024 Investor Presentation" (Exhibit 99.1) for presentations to existing and prospective investors. This presentation is incorporated by reference into the filing and is available on the company's website.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the distribution of the March 2024 Investor Presentation but does not provide specific text regarding guidance, outlook, or management commentary within the body of the 8-K itself.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into any registration statement, except as expressly stated.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (March 2024 Investor Presentation) for specific financial projections, strategic updates, and operational metrics not detailed in this 8-K summary.
- Verify the availability of the Investor Presentation on the company's official website at www.cardiodiagnosticsinc.com.
- Note that the company is classified as an Emerging Growth Company.
- Confirm the trading symbols: Common Stock (CDIO) and Redeemable Warrants (CDIOW) on The Nasdaq Stock Market LLC.